15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English Aligos Therapeutics提交了针对慢性乙型肝炎寡核苷酸候 ...
查看: 521|回复: 5
go

Aligos Therapeutics提交了针对慢性乙型肝炎寡核苷酸候选人ALG-010 [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2020-6-19 11:48 |只看该作者 |倒序浏览 |打印
Aligos Therapeutics Submits Clinical Trial Application for Chronic Hepatitis B Oligonucleotide Candidate ALG-010133
Email Print Friendly Share
June 18, 2020 10:18 ET | Source: Aligos Therapeutics

SOUTH SAN FRANCISCO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a private biotechnology company focused on the development of targeted antiviral therapies directed against chronic hepatitis B (CHB) and COVID-19 and therapeutics for NASH, today announced that it has submitted its first clinical trial application for a first-in-human Phase 1a/b study evaluating ALG-010133. ALG-010133 is a proprietary oligonucleotide S-antigen transport inhibiting oligonucleotide polymer (STOPS™) which is thought to act as an aptamer that interacts with specific proteins to decrease viral HBsAg levels, which is essential for enabling functional cure in CHB.

“We are excited to announce the achievement of this important developmental milestone for ALG-010133,” said Lawrence Blatt, Ph.D., MBA, Chief Executive Officer of Aligos. “With worldwide disease prevalence in the hundreds of millions, chronic hepatitis B patients are at significant risk of progression to liver fibrosis, cirrhosis, end stage liver disease, and hepatocellular carcinoma. Currently available therapies are given for life and rarely result in a sustained functional cure. Our goal is to develop a therapeutic regimen that can lead to high rates of functional cure for patients living with chronic hepatitis B. ”

Aligos’ STOPS program is the first of three classes of compounds in its CHB development portfolio, which also includes a capsid assembly modulator (CAM) and antisense oligonucleotide (ASO). Initially, Aligos plans to evaluate these in separate Phase 1 studies and then combine them in subsequent studies.  

About Aligos
Aligos Therapeutics, Inc. is a privately held biotechnology company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 as well as leveraging its expertise in liver diseases to create targeted therapeutics for NASH. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of best-in-class molecules.

Please visit www.aligos.com for more information.

Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
[email protected]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2020-6-19 11:48 |只看该作者
Aligos Therapeutics提交了针对慢性乙型肝炎寡核苷酸候选人ALG-010133的临床试验申请
电子邮件打印友好共享
美国东部时间2020年6月18日10:18 |资料来源:Aligos Therapeutics

2020年6月18日,加利福尼亚州南旧金山-全球生物技术公司Aligos Therapeutics,Inc.(Aligos)致力于开发针对慢性乙型肝炎(CHB)和COVID-19的靶向抗病毒疗法。 NASH的治疗药物今天宣布,已提交其首次人类临床试验申请,用于评估ALG-010133的首次人类1a / b期研究。 ALG-010133是一种专有的抑制寡核苷酸S抗原转运的寡核苷酸聚合物(STOPS™),被认为是与特定蛋白质相互作用以降低病毒HBsAg水平的适体,这对于实现CHB中的功能性治疗至关重要。

“我们很高兴宣布ALG-010133的这一重要发展里程碑的实现,” Aligos首席执行官MBA博士Lawrence Blatt说道。 “全世界疾病的流行率高达数亿,慢性乙型肝炎患者有发展为肝纤维化,肝硬化,终末期肝病和肝细胞癌的巨大风险。目前可用的治疗方法是终身有效的,很少能持续维持功能治愈。我们的目标是开发一种治疗方案,使慢性乙型肝炎患者能够获得较高的功能治愈率。”

Aligos的STOPS程序是其CHB开发产品组合中三类化合物中的第一类,还包括衣壳装配调节剂(CAM)和反义寡核苷酸(ASO)。最初,Aligos计划在单独的1期研究中对其进行评估,然后将其合并到以后的研究中。

关于阿里戈斯
Aligos Therapeutics,Inc.是一家私有生物技术公司,成立于2018年,其使命是成为病毒感染和肝病治疗的全球领导者。 Aligos致力于开发针对慢性乙型肝炎(CHB)和COVID-19的靶向抗病毒疗法,并利用其在肝脏疾病方面的专业知识为NASH创建靶向疗法。 Aligos的策略是利用其在肝脏疾病(尤其是病毒性肝炎)方面的专业知识和数十年的药物开发经验,以快速推进其同类最佳分子的生产。

请访问www.aligos.com了解更多信息。

媒体联络
艾米·乔布(Amy Jobe)博士
生命科学通讯
+1 315 879 8192
[email protected]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

3
发表于 2020-6-19 11:49 |只看该作者
ALG-010133与REP2139处于同一类别.

Rank: 10Rank: 10Rank: 10

现金
20677 元 
精华
帖子
12801 
注册时间
2013-12-29 
最后登录
2024-11-20 
4
发表于 2020-6-19 12:07 |只看该作者
StephenW 发表于 2020-6-19 11:49
ALG-010133与REP2139处于同一类别.

那我们就别关注rep了,多关注一下alg

Rank: 10Rank: 10Rank: 10

现金
20677 元 
精华
帖子
12801 
注册时间
2013-12-29 
最后登录
2024-11-20 
5
发表于 2020-6-19 12:08 |只看该作者
本帖最后由 newchinabok 于 2020-6-19 12:12 编辑
StephenW 发表于 2020-6-19 11:49
ALG-010133与REP2139处于同一类别.

那我们就多关注一下alg,少关注一下rep

Rank: 8Rank: 8

现金
887 元 
精华
帖子
807 
注册时间
2016-5-10 
最后登录
2024-3-31 
6
发表于 2020-6-19 13:05 |只看该作者
这是不是把rep逼死了,别这个alg二期结束,rep还没动静
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-21 00:56 , Processed in 0.013866 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.